Abstract: 13-Aza analogs of PGF2&agr; and methods of their use in treating glaucoma and ocular hypertension are disclosed.

Abstract: Methods and compositions for treating Kaposi's sarcoma and Epstein Barr virus using a a therapeutic derivative of a triterpenoid acid and derivatives thereof are disclosed.

Abstract: Arabinogalactan compositions are provided which are useful in a wide variety of different biomedical applications. In one embodiment, water soluble lipidated arabinogalactans are provided which include arabinogalactan with a limited proportion of lipophilic groups, such as long-chain hydrocarbon groups, covalently attached to free hydroxyl groups on the arabinogalactan. The lipidated arabinogalactans are water soluble and biocompatible and are useful for a wide variety of different biomedical applications. The lipidated arabinogalactans can be used, for example, to inhibit cell adhesion, and to inhibit infection or inflammation. The lipidated arabinogalactans further may be used as adjuvants, to inhibit metastasis, and in other therapeutic applications.

Abstract: Simple and efficient methods for formulating cereal beta glucan compositions that retard the natural gel forming properties of hydrocolloids and remain free flowing liquids is disclosed. The method employs a biological buffer system consisting of a zwitterionic salt that will vary pH with temperature. The resulting beta glucan preparation can be used directly or stored for future use.

Abstract: This invention provides a process for producing a betaine/amine oxide mixture. This process comprises reacting, in a liquid medium, an alkali metal &ohgr;-halocarboxylate with a first tertiary amine of the formula Ra2RbN, wherein each Ra group is a hydrocarbyl group which independently has from 1 to about 4 carbon atoms, and wherein the Rb group is a hydrocarbyl group which has from about 8 to about 24 carbon atoms, to produce a betaine product solution. To the betaine product solution is added a second tertiary amine of the formula Ra2RbN, wherein each Ra group is a hydrocarbyl group which independently has from 1 to about 4 carbon atoms, and wherein the Rb group is a hydrocarbyl group which has from about 8 to about 24 carbon atoms, to produce an amine/betaine mixture. The first and second tertiary amines can be separate portions of the same amine. Preferably, however, the first and second tertiary amines differ from each other.

Abstract: The present invention relates to pharmaceutical compositions comprising a positive modulator of a nicotinic receptor agonist, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.

Abstract: A method of enhancing the activity of lysosomal &agr;-Galactosidase A (&agr;-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

Abstract: Novel compositions containing at least one biologically active component derived from peat or similar composition, methods for their preparation and therapeutic uses for a variety of diseases, injuries, and conditions, including wound healing, pain, itch, inflammation, abnormal cell proliferation, or infections caused by fungal, bacterial, rickettsial or viral agents, psoriasis, allergic and other dermatitis, pruritis, eczema, actinic keratosis and similar conditions. In addition, the compositions can be used as diuretics, antiarrhythmics, and cardiac-stimulating agents, as well as for the treatment of mammalian diseases and disorders, including multiple drug resistance, cancers, asthma, rheumatoid arthritis, pain, wound healing, fungal disorders, and other inflammatory disorders. The compositions are derivable from peat or peat-related substances and may alternatively be synthetically produced.

Abstract: The present invention is directed to novel bidesmosidic saponin derivatives comprising a triterpene aglycone core substituted at positions 3 and 28 with a monosaccharide or an oligosaccharide which can be the same or different, and having an aldehyde group attached to the core, preferably at the 4-position. The novel derivatives include a lipophilic group that is covalently attached to the 4-position of a fucosyl group that is required in the 28-oligosaccharide substituent. These derivatives preferably have Formula I: wherein Z and R1 to R3 are defined herein. The present invention is also directed to pharmaceutical and veterinary compositions comprising one or more compounds of the present invention. These compositions may be employed as immunopotentiators in animals and humans. The present invention is also directed to methods of making these compounds and to methods of using these compounds as immunostimulating agents and as adjuvants.

Abstract: Arabinogalactan compositions are provided which are useful in a wide variety of different biomedical applications. In one embodiment, water soluble lipidated arabinogalactans are provided which include arabinogalactan with a limited proportion of lipophilic groups, such as long-chain hydrocarbon groups, covalently attached to free hydroxyl groups on the arabinogalactan. The lipidated arabinogalactans are water soluble and biocompatible and are useful for a wide variety of different biomedical applications. The lipidated arabinogalactans can be used, for example, to inhibit cell adhesion, and to inhibit infection or inflammation. The lipidated arabinogalactans further may be used as adjuvants, to inhibit metastasis, and in other therapeutic applications.

Abstract: This invention is directed to compounds of the following formula: wherein m is from 0-4; X is O or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: A delivery system is provided to reduce methane production in animals or to improve the weight gain of an animal. Embodiments include a delivery system comprising a volatile and/or water soluble antimethanogenic agent with cyclodextrin or a cyclodextrin-like compound.

Abstract: A process for preparation of crosslinked cellulosic products containing at least 30 wt. % cellulosic fibers and the polyanhydride crosslinked cellulosic products resulting therefrom wherein a cellulosic material is treated with an aqueous solution of a polycarboxylic acid formed by hydrolysis of a polyanhydride of the structure which comprises the reaction product of trimellitic anhydride and a diol in the mole ratio of from about 2.0:0.9 to about 2.0:1.1, wherein R is selected from the group consisting of alkyl, alkylene and cycloalkylene moieties of up to 12 carbon atoms and ethylene oxide and propylene oxide moieties of molecular weight up to about 6000, wherein said cellulosic material is impregnated with an aqueous solution of said polyanhydride, dried, and heated to a temperature of from about 120° C. to about 200° C.

Abstract: The invention provides versatile sialic acid C-glycoside precursors that are useful for preparing C-glycoside analogs of Gangliosides, peptides, and proteins, as well as synthetic intermediates useful for the preparation of the precursors, and synthetic methods useful for preparing the precursors and the intermediates. The invention also provides gangliosides, peptides, and proteins that comprise sialic acid C-glycoside components, as well as synthetic methods useful for the preparation of such compounds.

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.

Abstract: Method for preparing a salt of aspartylphenylalanine methyl ester from N-protected aspartylphenylalanine methyl ester involving cleaving off the protective group by treatment with an acid, in the course of which, first of all, N-protected aspartylphenylalanine methyl ester is caused to react in an aqueous medium and in the presence of methanol at a temperature of from 0 to 80° C. with from 0.8 to 2 equivalents of acesulphamic acid for at least such a time that the conversion to the salt of aspartylphenylalanine methyl ester and acesulphamic acid has been completed to an adequate degree, and then the salt formed in the first step is isolated in precipitated form at a temperature of 30° C. or lower.

Abstract: A method for treating liver dysfunction includes administering at least one member selected from a chitin oligosaccharide, a chitosan oligosaccharide and salts thereof, in an effective amount. As the chitin oligosaccharide, preferred is an oligosaccharide having a degree of polymerization of from 2 to 7. As the chitosan oligosaccharide, preferred is an oligosaccharide having a degree of polymerization of from 2 to 8. As the method for administration, it is preferred to add these oligosaccharides to foods, medicines or feeds, and to orally ingest them. However, when used as medicines, administration methods such as intravenous injection and muscular injection may be used.

Abstract: Camptothecin derivatives of camptothecin of formula (I) wherein the groups R1, R2 and R3 are as defined in the description are disclosed. The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index. Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.

Abstract: An R-configuration or S-configuration optically active secondary alcohol of the general formula (1), CH3C*H(OH)(CH2)mOCH(CnH2n+1)2  (1) wherein C* is an asymmetric carbon atom, m is an integer of 1 to 3, and n is an integer of 1 to 3, and a process for the production thereof, comprising optical resolution of a corresponding racemic alcohol by asymmetric trans-esterification, specifically using a lipase derived from Candida antarcia microorganism. The present invention can provide the novel optically active secondary alcohol having a methyl group on an asymmetric carbon and an alkoxy terminal having branched alkyl chains formed of the same numbers of carbon atoms, and an economical and simple process for the production thereof.

Abstract: The present invention relates to a method of producing xylose by chromatographic separation of the xylose from a sulphite cooking liquor containing for example xylose and xylonic acid. The xylose yield of the separation is affected by the xylonic acid and xylose content in the cooking liquor used in the separation and the amount of base cation used in the sulphite cooking.